Physician profile
Gerald Bristol
NPI 1720022122
$1,066.02
in general payments reported to CMS, 2019-2025
14 companies · $153 in 2025
The $153 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $82.03 · 2021: $95.73 · 2022: $126 · 2023: $101 · 2024: $352 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $607.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $211.09 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $206.51 | 2021-2025 | Qelbree |
| Corium, LLC | $126.26 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $96.34 | 2020-2022 | |
| Sanofi Pasteur INC. | $89.93 | 2021-2025 | |
| Tris Pharma INC | $72.23 | 2019 | |
| Collegium Pharmaceutical, INC. | $72.22 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $69.51 | 2019-2020 | |
| Glaxosmithkline, LLC. | $36.72 | 2020-2023 | Pediarix, Bexsero |
| Pfizer INC. | $23.85 | 2022 | |
| Vertical Pharmaceuticals, LLC | $16.64 | 2025 | Relexxii |
| Shire North American Group INC | $16.16 | 2019 | |
| Merck Sharp & Dohme LLC | $14.31 | 2023 | M-M-R II, Gardasil 9, Vaxelis |
| Genentech USA, INC. | $14.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Bristol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.